Unprofitable listed pharmaceutical companies pay attention! More than half of the product sales peak is less than this number!

1. Over the past 15 years, the average U.S. drug sales have peaked at about $800 million, with only 20 percent of products reaching $1 billion in the U.S., and surprisingly more than 50 percent of U.S. sales failing to reach $250 million.
2, on average, the third year of production will peak at 50 percent of sales, and drugs in the oncology sector will grow faster, reaching 50 percent of peak sales by the end of the second year, and these early sales can more accurately predict the drug's eventual peak sales.
, infectious diseases, immunology and cardiovascular diseases fell short of Wall Street expectations.
50 per cent more than smaller companies, with the average peak revenue from the launch of products from large pharmaceutical companies.
L.E.K., a global management consulting firm, has come to more than expected figures by tracking sales of more than 450 drugs in the United States between 2004 and 2016.
01.PCSK9 inhibitors, Iresha, O drug pain for pharmaceutical companies, the most painful may not be the difficult product development process, but by the high expectations of the product after the market sales less than expected.
pcSK9 inhibitors, for example, PCSK9 inhibitors offer a completely new treatment model against LDL-C.
At the time, research firms conservatively estimated that the market for PCSK9 inhibitors would exceed $9 billion, with annual sales of $3 billion, and that 20 percent of patients with abnormal blood lipids in the U.S. would favor the drugs, and there was plenty of room for incremental market growth.
PCSK9 inhibitors are recognized as the most effective fat-lowering targets in the field of fat-lowering drugs after statins.
in 2015, Sanofi and Regeneration jointly developed Arrocumab (Praluent), Amgen and Astellas launched the Iloyu single anti-injection Evolocumab (Repatha) has been approved for the market, and is considered to be an important target for heavy bomb drugs.
In December 2017, Amgen Bio's Iloyu monoantigen injection was used in adult patients with atherosclerosis cardiovascular disease to prevent myocardial infarction, stroke, and coronary artery blood transport reconstruction, becoming the first PCSK9 inhibitor to be approved for this type of adaptation.
, despite adequate clinical data and assurance of efficacy, sales of the two drugs were far below expectations and market acceptance was slow.
industry analysis, the main reason is that PCSK9 single anti-market, the price has no advantage, the annual cost of using PCSK9 single-resistance was once 350 times his statins.
2017, Alirocumab's sales were $195 million, while Evolocumab's sales were $319 million, according to the company.
fourth year of its listing, the company's total was $857 million.
it was not until 2018 that Amjin reached an agreement with Sanofi to lower the price of the drug from $14,000/year to $4,500-$6600/year, a 60 percent reduction.
but the effectiveness of this strategy has not been significant, with Evolocumab growth dropping significantly to 20% in 2019 and Alirocumab sales falling short of overall sales in 2018.
AstraZeneta's EGFR-targeted treatment, Iressa, has followed in the efficacy of different species, with the product's efficacy in the "West not bright."
, which went on sale in 2003, is AstraZenecom's first oral lung cancer-targeted drug, which has transformed the traditional treatment of lung cancer and become an innovative breakthrough in the field of cancer.
a Clinical Trial called ISEL in December 2004 showed that Irisa could not extend the lifespan of the overall patient, and the FDA subsequently said it would consider withdrawing it from the market.
"Irisha" has no advantage in extending the life expectancy of Western patients, but it is more effective for Asians, which led AstraZeneta to stop promoting in the United States and withdraw its application to register in the European market, which has shrunk from a global to Asia-based market.
2005 AstraZeneta, Irrisha listed in China, the price of 5000 yuan / box, and then through national negotiations, the price from 5000 yuan to 2358 yuan.
first round of volume purchases, AstraZeneta won for $547, a drop of more than 76 per cent.
there's an O-drug that's not a single line of recent disasters.
the world's first approved PD-1 inhibitor halo, in 2019 for BMS contributed $7.204 billion in sales of O drugs, frequently "water reverse."
In the end of 2020, BMS withdrew O-drugs in the United States "after receiving platinum drug chemotherapy and at least one other treatment after disease progression of small cell lung cancer" adaptation application, and then on January 7, the National Institute for Health and Clinical Optimization of the United Kingdom issued a notice that "Odivo" is not recommended for the treatment of relapse or metastatic head and neck squamous cell carcinoma (SCCHN) adult patients with progression of the disease during or after platinum chemotherapy.
this will have a direct impact on the development of O drugs in the lung cancer market, as well as the UK head and neck cancer market.
expansion of the drug is an important step to expand the market, and O drug small cell lung cancer adaptation progress is not good, but also give competitors a opportunity to take advantage of.
in the Chinese market, PD-1 price war has started, in the 2020 health care negotiations, the four domestic PD-1 price reduction of 80%, all successfully entered health insurance, and O drug failed to be selected.
already have eight drugs on the market in China.
Evaluate Pharma had forecast O-drug sales of $7.80 billion in 2019 and close to $12 billion by 2024.
but from the current sales figures, it is not as good as expected and the momentum for future growth is likely to weaken further.
02. Domestic "-B" innovative pharmaceutical companies are more wary that these large MNCs may be able to withstand the impact of below-expected product sales, and LEK surveys show that the average peak revenue from products launched by large pharmaceutical companies is 50 percent higher than the average peak of products issued by small participants.
, however, for small, emerging biopharmaceutical companies, these conditions could be fatal.
e.g. EGFR inhibitor AC0010 (Avetinib), developed by Eisen Pharmaceuticals, is China's first original third-generation EGFR targeted inhibitor, mainly used to treat non-small cell lung cancer with EGFR T790M mutation positive, is the 12th Five-Year National "major new drug creation" one of the important achievements of science and technology.
be included in the priority review process for the launch of new drugs in 2018.
incomplete statistics, from September 2014 to early 2018 to complete the Evitini China registered clinical research, Eisen has continued to invest hundreds of millions of dollars in research and development.
But the drug has not been approved for sale, and in the absence of commercialization of new drugs, Eisen Pharmaceuticals has been building a sales marketing team since 2018, and in 2019, Eisen Pharmaceuticals has adjusted its commercialization strategy to abolish its marketing team.
for domestic innovative pharmaceutical companies, if successful, the next test is the commercialization of enterprises.
half of the "-B" innovative pharmaceutical companies (unprofitable listed pharmaceutical companies) are expected to enter the commercialization phase by 2021, according to a report by Societe Generale.
such as Corning Jerry, Asahi Pharmaceuticals, Keystone Pharmaceuticals, Rongchang Bio, etc. are expected to achieve the first product launch and commercialization in 2021.
But there are also investors who say that after the wave of Chinese innovative drug companies going public in 2020, there will be a ripple effect if subsequent companies' heavy-weight products are clinically unfavourable, or if new products go on sale less than expected, and that's when the bubble bursts.
looking at the U.S. market, L.E.K. analysis shows that more than 90 percent of products in the first year earn less than $250 million in the U.S. and more than 70 percent in the second year less than $250 million.
few emerging biopharmaceutical companies have launched their first products, exceeding analysts' sales expectations, underscoring the difficulty of commercial execution for smaller companies.
L.E.K. points out that small biopharmaceutical companies can innovate and develop best-in-class products than large biopharmaceutical companies, more than 50 percent of which are innovative.
, small biopharmaceutical companies no longer have the advantage when it comes to the commercialization and life cycle management of new drugs.
L.E.K. has proposed planning for an early market, and even companies with great products can face significant challenges if they are not prepared to go to market.
L.E.K. recommends that biopharmaceutical companies begin considering start-up plans at least 36 months before they first get market authorization, and that it is critical to establish a cross-functional team to support and track product launches.
given the limited resources and capabilities of small pharmaceutical companies, serious consideration should be given to partnerships, and executives should think strategically about commercialization options and carefully evaluate opportunities for collaboration.
.E.K. stressed the need for small biotech companies that are about to launch their first products to exercise caution in managing capital market expectations.
if the number of patients is exaggerated, market access levels are misjudged, or market competitive dynamics are misjudged, market expectations can be seriously inconsistent with actual developments.